KKR Real Estate Finance Trust Inc. (KREF) Earnings
KKR Real Estate Finance Trust Inc. is expected to report next earnings on July 22, 2026 (in NaN days), with a consensus EPS estimate of $-0.57. KREF has beaten EPS estimates in 7 of its last 12 reported quarters (average surprise -175.4% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 23, 2026 | $0.15 | $-0.06 | -139.8% | $35M | +23.0% |
| Feb 3, 2026 | $0.13 | $0.22 | +69.2% | $108M | +298.9% |
| Oct 21, 2025 | $0.01 | $-0.03 | -400.0% | $25M | -2.8% |
| Jul 22, 2025 | $-0.16 | $-0.53 | -231.3% | $119M | +267.3% |
| Apr 23, 2025 | $0.17 | $-0.15 | -188.2% | $31M | -11.0% |
| Feb 3, 2025 | $0.08 | $0.31 | +287.5% | $34M | +6.2% |
| Oct 21, 2024 | $0.31 | $0.40 | +29.0% | $37M | +3.8% |
| Jul 22, 2024 | $0.33 | $0.40 | +21.2% | $156M | +326.8% |
| Feb 6, 2024 | $0.45 | $0.47 | +4.4% | $44M | -5.4% |
| Jul 24, 2023 | $0.28 | $0.48 | +71.4% | $44M | -4.5% |
| Feb 7, 2023 | $0.49 | $0.18 | -63.3% | $49M | -4.5% |
| Jul 25, 2022 | $0.42 | $0.48 | +14.3% | $42M | -6.4% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · April 23, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
• 2026 is a transition year with focus on narrowing share price and book value gap. Priorities: executing resolution strategy on watch list assets and legacy office exposures, and positioning REO portfolio for liquidity. • Goal to reduce legacy office exposure from 21% to under 10%, resolve all watch list loans by year end, address life science exposure with goal to modify 100%, and originate new investments with loans from 2024 - 2026 expected to be 50% of portfolio by year end. • Announced dividend reduction to 10 cents per share per quarter, with board authorizing $75 million share repurchase program. • Changes to watch list: downgraded Philadelphia office assets and Boston Life Science asset, upgraded Cambridge Life Science. Recorded CECL provisions of 74 million. • Actively managing REO portfolio with near, medium, and longer-term monetization buckets. Estimate potential to generate over 15 cents per share of incremental quarterly earnings from REO monetization. • At quarter end, $653 million liquidity, $184 million originations, $415 million repayments. First three weeks of second quarter closed over $400 million new loans. Debt to equity ratio 2.2 times, total leverage 4 times consistent with target range.
Guidance
• Dividend reduced to 10 cents per share per quarter, aligned with expectations for distributable earnings per share before realized losses. • Expect earnings to trough in second half of 2026 into first half of 2027, then distributable earnings per share to increase. • Board authorized $75 million share repurchase program providing flexibility to deploy capital. • Loans originated between 2024 - 2026 expected to be ~50% of portfolio by year end, indicating turnover into newer vintage assets with improved earnings potential.
Segment performance
For the first quarter of 2026, gap net loss was $62 million or negative 96 cents per share. Book value as of March 31st, 2026 was $11.87 per share. Distributable loss was $4 million or negative 6 cents per share. Distributable earnings before realized losses was $13 million, or 20 cents per share. Paid a 25-cent cash dividend in April. No specific product segments detailed with revenue contribution % as it's not focused on product lines but overall company performance.
Risks & headwinds
• Uncertainty in market conditions affecting asset valuations and resolutions. • Potential challenges in resolving watch list loans and legacy office exposures as expected. • Market dynamics impacting REO portfolio monetization and value realization. • Fluctuations in earnings due to portfolio repositioning and market variability. • Risks associated with life science exposure modifications and potential losses. • Impact of external factors like oil prices, inflation, AI on company performance and valuations.
Analyst Q&A
Q: Portfolio target of 50% newer vintage loans by year end implies billion to billion two origination activity, are we in ballpark?
A: Matt says it's in the ballpark, depends a bit on share buyback amount.
Q: Use of liquidity for originations and buybacks, tied to REO sales?
A: Most liquidity from loan repayments, not tied to REO sales timing.
Q: On watch list, expectations for remaining assets repaid vs modified?
A: Goal to clear all by end of year, combination of modifications, note sales, some sold by sponsors.
Q: Dividend and earnings X losses, expect earnings to cover 10 cents?
A: Matt says expect to cover on annualized intermediate basis, but quarters may have noise.
Q: $42 million CMBS investment, attractive vs bridge loans?
A: Evaluated on relative value, providing duration and access to different markets.
Q: Green shoots in life science leasing?
A: Jade says seeing revitalization in some areas, tenants coming back but early.
Q: Credit risk management, migration from risk three to five?
A: Patrick says normal progression is three, four, five, majority follow that, analysis done quarterly.
Q: Contemplation of fee cut from KKR during transition?
A: Matt says evaluating all options.
Q: Mountain View lease term details?
A: Subject to NDA, long-term lease thought to trade like net lease.